Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.6K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.6K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

1.5K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

1.6K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.6K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.4K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.4K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.9K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emerging Paediatric Uses of Dupilumab Beyond Approvals.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Health inequities in pediatric anaphylaxis: A policy framework and call to action for equitable care from SIAIP allergy prevention commission.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Novelties in the pragmatic management of anaphylaxis in pediatric age.

European journal of pediatrics·2026
Same author

Application of machine learning to predict bronchiolitis severity in children: a single-centre retrospective cohort study.

European journal of pediatrics·2026
Same author

Pragmatic management of acute cough in children and adolescents: an updated position paper by the Italian Society of Pediatric Allergy and Immunology (SIAIP).

Allergologia et immunopathologia·2026
Same author

Mapping of pediatric allergy structures in Italy: a nationwide survey.

Italian journal of pediatrics·2026
Same journal

Developmental and behavioral profile in a domestic adoptees sample: a new challenge for the pediatrician.

Minerva pediatrica·2020
Same journal

A new approach to the diagnosis of short stature.

Minerva pediatrica·2020
Same journal

Management of the main endocrine and diabetic disorders in children.

Minerva pediatrica·2020
Same journal

Kounis Syndrome: a pediatric perspective.

Minerva pediatrica·2020
Same journal

Human inborn errors of immunity caused by defects of receptor and proteins of cellular membrane.

Minerva pediatrica·2020
Same journal

Tall stature in children and adolescents.

Minerva pediatrica·2020
See all related articles

Related Experiment Video

Updated: Dec 13, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

4.5K

Pidotimod in allergic diseases.

Sara Manti1, Giuseppe F Parisi2, Maria Papale2

  • 1Unit of Pediatric Respiratory, Department of Clinical and Experimental Medicine, AOU Vittorio Emanuele Polyclinic, San Marco Hospital, University of Catania, Catania, Italy - saramanti@hotmail.it.

Minerva Pediatrica
|August 1, 2020
PubMed
Summary
This summary is machine-generated.

Pidotimod is an immunostimulant that enhances both innate and adaptive immunity. It offers a promising therapeutic strategy for allergic diseases in children by improving immune function.

More Related Videos

Murine Model of Epicutaneously-Induced Immunomodulation
09:06

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

339
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

653

Related Experiment Videos

Last Updated: Dec 13, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

4.5K
Murine Model of Epicutaneously-Induced Immunomodulation
09:06

Murine Model of Epicutaneously-Induced Immunomodulation

Published on: June 24, 2025

339
A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

653

Area of Science:

  • Immunology
  • Pediatric Allergy
  • Pharmacology

Background:

  • Allergic diseases are increasing, necessitating novel therapeutic approaches.
  • Immunostimulants are explored for preventing and treating pediatric allergic conditions.
  • Pidotimod is a biologically active substance with known immunomodulatory effects.

Purpose of the Study:

  • To evaluate pidotimod's efficacy in managing allergic diseases in pediatric populations.
  • To investigate pidotimod's impact on innate and adaptive immune responses.
  • To assess pidotimod as a safe and effective therapeutic option.

Main Methods:

  • Clinical studies involving pediatric patients with allergic disorders.
  • Assessment of immune system parameters before and after pidotimod administration.
  • Analysis of changes in innate and adaptive immunity markers.

Main Results:

  • Pidotimod demonstrated the ability to ameliorate innate immunity.
  • Pidotimod was effective in improving adaptive immune responses.
  • The drug enhanced immune system properties in children with allergic disorders.

Conclusions:

  • Pidotimod shows potential as a specific, effective, and safe therapeutic agent for pediatric allergic diseases.
  • Enhancement of both innate and adaptive immunity by pidotimod addresses key immune dysfunctions in allergies.
  • Further research may solidify pidotimod's role in allergy management.